Lymph node metastatic patterns of gastric carcinoma with a combination of adenocarcinoma and neuroendocrine carcinoma components

Table 1 Clinicopathological features among lymph node metastasis patterns, n (%)

Parameters	NEC	AC	Both	Total	χ2 value	P value
pT stage					8.36	0.015
pT1-2 stage	3 (25)	9 (75)	0 (0)	12 (100)
pT3-4 stage	24 (42.9)	18 (32.1)	14 (25)	56 (100)
LVI					0.917	0.68
-	4 (57.1)	2 (28.6)	1 (14.3)	7 (100)
+	23 (37.7)	25 (41)	13 (21.3)	61 (100)
PNI					1.267	0.582
-	10 (50)	7 (35)	3 (15)	20 (100)
+	17 (35.4)	20 (41.7)	11 (22.9)	48 (100)
NEC percentage (%)					12.604	0.008
1-29	1 (12.5)	5 (62.5)	2 (25)	8 (100)
30-70	13 (31.7)	20 (48.8)	8 (19.5)	41 (100)
71-99	13 (68.4)	2 (10.5)	4 (21.1)	19 (100)
Histology					3.350	0.484
Small cell	9 (40.9)	8 (36.4)	5 (22.7)	22 (100)
Large cell	14 (34.1)	18 (43.9)	9 (22)	41 (100)
Both	4 (80)	1 (20)	0 (0)	5 (100)
Lauren type					12.46	0.01
Intestinal type	23 (56.1)	12 (29.3)	6 (14.6)	41 (100)
Diffuse type	1 (9.1)	6 (54.5)	4 (36.4)	11 (100)
Mixed type	3 (18.8)	9 (56.3)	4 (25)	16 (100)
LN periosteal violation					0.269	0.94
No	8 (36.4)	10 (45.5)	4 (18.2)	22 (100)
Yes	15 (37.5)	16 (40)	9 (22.5)	40 (100)
Syn					1.629	1.00
-	0 (0)	1 (100)	0 (0)	1 (100)
+	27 (40.3)	26 (38.8)	14 (20.9)	67 (100)
CgA					1.994	0.44
-	11 (52.4)	7 (33.3)	3 (14.3)	21 (100)
+	16 (34)	20 (42.6)	11 (23.4)	47 (100)
CD56					2.837	0.22
-	4 (25)	9 (56.3)	3 (18.8)	16 (100)
+	22 (45.8)	16 (33.3)	10 (20.8)	48 (100)
Sex					0.345	1.00
Female	3 (37.5)	3 (37.5)	2 (25)	8 (100)
Male	24 (40)	24 (40)	12 (20)	60 (100)
Age (year)					4.546	0.29
≤ 45	0 (0)	2 (100)	0 (0)	2 (100)
45-70	23 (45.1)	19 (37.3)	9 (17.6)	51 (100)
≥ 70	4 (26.7)	6 (40)	5 (33.3)	15 (100)
With NAC					0.339	0.94
No	19 (38)	20 (40)	11 (22)	50 (100)
Yes	8 (44.4)	7 (38.9)	3 (16.7)	18 (100)
Location					11.041	0.004
EGJ	20 (58.8)	8 (23.5)	6 (17.6)	34 (100)
Non-EGJ	7 (20.6)	19 (55.9)	8 (23.5)	34 (100)

NEC: Neuroendocrine carcinoma; AC: Adenocarcinoma; pT: Postoperative pathological tumour; LVI: Lymphatic invasion; PNI: Perineural invasion; LN: Lymph node; Syn: Synaptophysin; CgA: Chromogranin A; CD56: Cluster of differentiation 56; NAC: Neoadjuvant chemotherapy; EGJ: Esophagogastric junction.

Table 2 Multivariate logistic regression analysis of independent risk factors

Indicators	β	SE	Wald	P values	OR	95%CI
pT stage	1.060	0.955	1.230	0.267	2.885	0.44-18.762
NEC percentage (%)	1.945	0.706	7.588	0.006	6.991	1.752-27.891
Tumour location	-2.015	0.759	7.035	0.008	0.133	0.030-0.591
Lauren type	-0.896	0.479	3.507	0.061	0.408	0.160-1.043
Constant	-1.780	1.296	1.887	0.169

pT: Postoperative pathological tumour; NEC: Neuroendocrine carcinoma; OR: Odds ratio; CI: Confidence interval.

Table 3 Clinicopathological features among lymph node metastasis patterns in adenoneuroendocrine mixed gastric cancer patients who did not undergo neoadjuvant therapy, n (%)

Parameters	NEC	AC	Both	Total	χ2 value	P value
pT stage					5.4	0.045
pT1-2 stage	3 (30)	7 (70)	0 (0)	10 (100)
pT3-4 stage	16 (40)	13 (32.5)	11 (27.5)	40 (100)
LVI					1.6	0.344
-	3 (60)	2 (40)	0 (0)	5 (100)
+	16 (35.6)	18 (40)	11 (24.4)	45 (100)
PNI					1.89	0.396
-	8 (50)	6 (37.5)	2 (12.5)	16 (100)
+	11 (32.4)	14 (41.2)	9 (26.5)	34 (100)
NEC percentage (%)					9.38	0.038
1-29	1 (14.3)	4 (57.1)	2 (28.6)	7 (100)
30-70	8 (27.6)	14 (48.3)	7 (24.1)	29 (100)
71-99	10 (71.4)	2 (14.3)	2 (14.3)	14 (100)
Histology					5.80	0.185
Small cell	9 (52.9)	5 (29.4)	3 (17.6)	17 (100)
Large cell	7 (24.1)	14 (48.3)	8 (27.6)	29 (100)
Both	3 (75)	1 (25)	0 (0)	4 (100)
Lauren type					14.92	0.002
Intestinal type	17 (60.7)	7 (25)	4 (14.3)	28 (100)
Diffuse type	0 (0)	5 (62.5)	3 (37.5)	8 (100)
Mixed type	2 (14.3)	8 (57.1)	4 (28.6)	14 (100)
LN periosteal violation					0.13	1.00
No	6 (40)	6 (40)	3 (20)	15 (100)
Yes	12 (37.5)	13 (40.6)	7 (21.9)	32 (100)
Syn					1.59	1.00
-	0 (0)	1 (100)	0 (0)	1 (100)
+	19 (38.8)	19 (38.8)	11 (22.4)	49 (100)
CgA					2.25	0.298
-	8 (53.3)	4 (26.7)	3 (20)	15 (100)
+	11 (31.4)	16 (45.7)	8 (22.9)	35 (100)
CD56					4.0	0.143
-	2 (18.2)	7 (63.6)	2 (18.2)	11 (100)
+	17 (47.2)	11 (30.6)	8 (22.2)	36 (100)
Sex					0.51	0.865
Female	3 (50)	2 (33.3)	1 (16.7)	6 (100)
Male	16 (36.4)	18 (40.9)	10 (22.7)	44 (100)
Age (year)					3.62	0.494
≤ 45	0 (0)	1 (100)	0 (0)	1 (100)
45-70	16 (44.4)	13 (36.1)	7 (19.5)	36 (100)
≥ 70	3 (23.4)	6 (46.2)	4 (30.7)	13 (100)
Location					4.31	0.116
EGJ	12 (52.2)	6 (26.1)	5 (21.7)	23 (100)
Non-EGJ	7 (25.9)	14 (51.9)	6 (22.2)	27 (100)

NEC: Neuroendocrine carcinoma; AC: Adenocarcinoma; pT: Postoperative pathological tumour; LVI: Lymphatic invasion; PNI: Perineural invasion; LN: Lymph node; Syn: Synaptophysin; CgA: Chromogranin A; CD56: Cluster of differentiation 56; NAC: Neoadjuvant chemotherapy; EGJ: Esophagogastric junction.

Table 4 Multivariate logistic regression analysis of independent risk factors in adenoneuroendocrine mixed gastric cancer patients who did not undergo neoadjuvant therapy

Indicators	β	SE	Wald	P values	OR	95%CI
pT	0.983	1.033	0.906	0.341	2.674	0.353-20.256
NEC percentage (%)	1.749	0.789	4.917	0.027	5.750	1.225-26.984
Lauren type	-1.306	0.588	4.924	0.026	0.271	0.085-0.859
Tumour location	-1.714	0.882	3.777	0.052	0.180	0.032-1.015
Constant	-1.336	1.414	0.892	0.345

pT: Postoperative pathological tumour; NEC: Neuroendocrine carcinoma; OR: Odds ratio; CI: Confidence interval.